National Cancer Institute (NCI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Cancer Institute (NCI) sits in the top decile of US sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count).
National Cancer Institute (NCI): 3,257 sponsored US clinical trials, 326 recruiting.
National Cancer Institute (NCI) sponsors 3,257 registered US clinical trials on ClinicalTrials.gov, 326 of them currently recruiting, and 2,051 completed. 193 of these trials are in Phase 3-4 (later-stage) and 2,628 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignant Solid Neoplasm, with 67 trials.
Top-decile sponsor footprint
National Cancer Institute (NCI) ranks in the top decile of sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
3,257 total, page 60 of 66
International Cooperation for Post-Cherynobyl NIS Thyroid Tissue and Data Banks
NCT00339274
Vaccine Therapy in Treating Patients With Metastatic Melanoma
NCT00019994
Vaccine Therapy in Treating Patients With Unresectable Metastatic Melanoma
NCT00004148
Endostatin in Treating Patients With Advanced Solid Tumors
NCT00004229
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
NCT00004242
Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
NCT00004862
Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer
NCT00004189
Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura
NCT00019825
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
NCT00019669
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
NCT00004241
Oxaliplatin in Cancer Patients With Impaired Kidney Function
NCT00001835
Effects of Raloxifene on Hormone Levels
NCT00026962
506U78 in Treating Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
NCT00003837
Monoclonal Antibody Plus Chemotherapy in Treating Patients With Advanced Colorectal Cancer That Overexpresses HER2
NCT00003995
Celecoxib in Preventing the Damaging Effects of Sunburn in Healthy Volunteers
NCT02099136
Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer
NCT00004089
Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
NCT00001832
Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer
NCT00019656
Sarcosinamide Nitrosourea in Treating Patients With Metastatic or Unresectable Solid Tumors
NCT00004079
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
NCT00004074
Study of Etoposide in Breast Cancer Patients
NCT00026949
Motexafin Gadolinium Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma
NCT00003909
Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2
NCT00003992
p53 Vaccine for Ovarian Cancer
NCT00001827
Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants
NCT00001830
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
NCT00019630
Observation of HIV-Infected Children Receiving Protease Inhibitor and Reverse Transcriptase Inhibitor
NCT00001826
6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia
NCT00003997
Broxuridine Plus Surgery in Treating Patients With Stage I or Stage II Prostate Cancer
NCT00003832
Vaccine Therapy in Treating Patients With Metastatic Melanoma
NCT00019734
UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia
NCT00019838
Oxaliplatin Plus Capecitabine in Treating Patients With Colorectal, Appendix, or Small Bowel Cancer
NCT00019773
Characterization of the Pharmacokinetics of Oral Selenium Compounds in Humans Before and Following Supplementation
NCT00342966
Combination Drug Treatment of Pediatric HIV Infection
NCT00001818
Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia
NCT00003620
Bryostatin 1 in Treating Patients With Metastatic Kidney Cancer
NCT00003968
Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia
NCT00003934
Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
NCT00019708
Examination of Clinical and Laboratory Abnormalities in Patients With Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy
NCT00001813
Intraprostatic Androgenicity in Relation to Circulating Levels of Hormones and Polymorphisms of Hormone-Related Genes: A Methodologic Study
NCT00342433
The Impact of Starbright World on Children Being Treated at the NIH
NCT00001816
O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors
NCT00003765
A Pilot Study to Investigate the Clinical Utility of the Peregrine Monte Carlo Dose Calculation System for Radiation Therapy Treatment Planning
NCT00026936
Combination Chemotherapy in Treating Patients With Stage III Colon Cancer
NCT00003835
Irofulven in Treating Patients With Metastatic Breast Cancer
NCT00003796
Chemotherapy in Treating Children With Recurrent or Refractory Sarcomas
NCT00003745
Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Rectal Cancer
NCT00003799
(1)H-Nuclear Magnetic Resonance Spectroscopic Imaging of the Brain in Patients Who Receive Neurotoxic Therapy
NCT00001807
Methods in Education for Breast Cancer Genetics
NCT00001806
An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections
NCT00001810
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1199 |
| Phase 2 | 1429 |
| Phase 3 | 193 |
Therapeutic Areas
What is open in the National Cancer Institute (NCI) pipeline
326 recruiting of 3,257 indexed (10% open); 2,051 completed (63%).
Phase mix: 193 late (III/IV) vs 2,628 early (I/II) (early-phase heavy).
Top condition: Advanced Malignant Solid Neoplasm (67 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.